State, local access to federal device contracts would cost $1.35 bil. a year -- HIMA rep.
This article was originally published in The Gray Sheet
Executive Summary
STATE, LOCAL PARTICIPATION IN FEDERAL MEDICAL DEVICE CONTRACTS WOULD ADD $1.35 BIL. in annual costs to the federal government, according to results of a study released by Thomas Gunerman, president and CEO of Intersurgical, at a July 27 hearing before the House Committee on Small Business. Gunerman, who represented the Health Industry Manufacturers Association, cited a study conducted by Muse & Associates at HIMA's request which suggested that federal government cost increases experienced with the Medicaid prescription drug rebate program would be repeated for devices under Sec. 1555 of the Federal Acquisition Streamlining Act of 1994 (FASA).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.